Avanafil

Avanafil is a highly selective PDE5 inhibitor distinguished by rapid onset of action, used for the treatment of erectile dysfunction. Simson Pharma's Avanafil reference standard and impurities support stability-indicating assay development for this fast-acting PDE5-inhibitor therapy.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Avanafil Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Avanafil
Avanafil Acid Impurity
2-Pyrimidinemethanamine Hydrochloride
R-Avanafil
Avanafil impurity 4
Avanafil Dichloro Impurity
Avanafil Dimer Impurity
Avanafil Diamine Impurity
(S)-2-(2-(Hydroxymethyl)pyrrolidin-1-yl)-4-((4-methylbenzyl)amino)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
Avanafil Dimer Impurity (mixture of isomers)
Avanafil Impurity 28
Avanafil Dimer Ester Impurity
N-Nitroso Avanafil
Avanafil Impurity 30
Avanafil Impurity 31
Avanafil Related Compound 1
Avanafil Impurity 22
Avanafil Impurity 1

Isotope Labelled Compounds

Avanafil-13C d5
Avanafil 13CD3
Avanafil D4